New Blood Thinner Promises to Stop Clots Without Causing Bleeding

Monday, 17 Jun 2013 12:49 PM

 

Share:
A    A   |
   Email Us   |
   Print   |
   Forward Article  |
  Copy Shortlink

British scientists have won early financial backing for a new kind of anticoagulant drug they believe may prevent dangerous blood clots without causing bleeding - a previously unachievable goal.
 
Index Ventures, working with GlaxoSmithKline and Johnson & Johnson via an early-stage biotech fund, said on Monday it was investing $11 million in XO1, a new company set up to develop the experimental medicine.
 
Called ichorcumab, the new drug is still miles from reaching the market - clinical trials are only slated to start within the next two years - but the product may create a stir in a commercially important field, given its unusual properties.
 
It was created by scientists at the University of Cambridge and Addenbrooke's Hospital following the observation of a patient in her 50s whose blood appeared unable to clot but who had no major bleeding problems after a head injury in 2008.
 
The researchers pinpointed her unusual response to a unique antibody, which they went on to synthesise.
 
Currently, anticoagulants are used to reduce the risk of heart attacks and strokes, but doctors have to weigh up carefully their benefits against the danger of triggering uncontrolled bleeding.
 
"This antibody can deliver a high degree of anticoagulation without increased bleeding; we've never seen that before," said Jim Huntingdon, a professor at the Cambridge Institute of Medical and one of the scientists behind the project.
 
Warfarin has been a mainstay of anticoagulation therapy for many years. More recently new drugs have been launched, including Boehringer Ingelheim's Pradaxa, Bayer and J&J's Xarelto, and Pfizer and Bristol-Myers Squibb's Eliquis.
 
The $11 million start-up cash for XO1 comes from a $200 million life sciences fund launched last year by Index in an unusual collaboration with GSK and J&J. The fund aims to invest in companies with just one or two projects - a so-called "asset-centric" approach.
 
Under the three-way deal, the venture capital firm controls all investment decisions and the two drugmakers have no preferential rights to acquire any new drugs, although they do get a useful inside view should they wish to compete for assets.

© 2014 Thomson/Reuters. All rights reserved.

Share:
   Email Us   |
   Print   |
   Forward Article  |
  Copy Shortlink
Around the Web
Join the Newsmax Community
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

New Cancer Weapons: Magnets, Lasers, 'Nanoballons'

Wednesday, 16 Apr 2014 09:38 AM

Medical scientists are rapidly developing new weapons against cancer that use lasers, magnets, and 'nanoballoons' — tiny . . .

Why Latest Flu Season Was No Pandemic

Wednesday, 16 Apr 2014 08:10 AM

The H1N1 flu was the predominant influenza strain in the United States this year, but it packed a lot less punch than in . . .

Do Genetics Determine Our Motivation to Be Fit?

Wednesday, 16 Apr 2014 07:52 AM

Could genes be to blame for a lack of motivation to hit the gym? A recent study conducted at the University of Missouri  . . .

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved